6851-51-0

Usage

Uses

Used in Pharmaceutical Industry:
N-carbamoylputrescine is used as an intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its role in polyamine biosynthesis makes it a key component in the development of drugs targeting certain biological processes.
Used in Agricultural Industry:
N-carbamoylputrescine is used as a growth regulator in plants for [application reason]. Its involvement in the production of polyamines, which are essential for plant growth and development, makes it a valuable tool in enhancing crop yields and improving plant health.
Used in Biochemical Research:
N-carbamoylputrescine is used as a research compound in biochemical studies for [application reason]. Its involvement in various metabolic pathways and its role as a substrate and product in biochemical reactions make it an important molecule for understanding cellular processes and mechanisms.
Used in Chemical Synthesis:
N-carbamoylputrescine is used as a building block in the synthesis of complex organic compounds for [application reason]. Its unique structure and reactivity make it a valuable component in the creation of new molecules with potential applications in various industries.

InChI:InChI=1/C5H13N3O/c6-3-1-2-4-8-5(7)9/h1-4,6H2,(H3,7,8,9)

Upstream product

• 306-60-5 1-(4-aminobutyl)guanidine 

Downstream Products

• 110-60-1 1,4-diaminobutane 

Relevant academic research and scientific papers

Characterization and inactivation of an agmatine deiminase from Helicobacter pylori

Helicobacter pylori encodes a potential virulence factor, agmatine deiminase (HpAgD), which catalyzes the conversion of agmatine to N-carbamoyl putrescine (NCP) and ammonia - agmatine is decarboxylated arginine. Agmatine is an endogenous human cell signaling molecule that triggers the innate immune response in humans. Unlike H. pylori, humans do not encode an AgD; it is hypothesized that inhibition of this enzyme would increase the levels of agmatine, and thereby enhance the innate immune response. Taken together, these facts suggest that HpAgD is a potential drug target. Herein we describe the optimized expression, isolation, and purification of HpAgD (10-30 mg/L media). The initial kinetic characterization of this enzyme has also been performed. Additionally, the crystal structure of wild-type HpAgD has been determined at 2.1 A resolution. This structure provides a molecular basis for the preferential deimination of agmatine, and identifies Asp198 as a key residue responsible for agmatine recognition, which has been confirmed experimentally. Information gathered from these studies led to the development and characterization of a novel class of haloacetamidine-based HpAgD inactivators. These compounds are the most potent AgD inhibitors ever described.

Occurrence of agmatine pathway for putrescine synthesis in Selenomonas ruminatium

Selenomonas ruminantium synthesizes cadaverine and putrescine from L-lysine and L-ornithine as the essential constituents of its peptidoglycan by a constitutive lysine/ornithine decarboxylase (LDC/ODC). S. ruminantium grew normally in the presence of the specific inhibitor for LDC/ODC, DL-α-difluoromethylornithine, when arginine was supplied in the medium. In this study, we discovered the presence of arginine decarboxylase (ADC), the key enzyme in agmatine pathway for putrescine synthesis, in S. ruminantium. We purified and characterized ADC and cloned its gene (adc) from S. ruminantium chromosomal DNA. ADC showed more than 60% identity with those of LDC/ODC/ADCs from Gram-positive bacteria, but no similarity to that from Gram-negative bacteria. In this study, we also cloned the aguA and aguB genes, encoding agmatine deiminase (AguA) and N-carbamoyl-putrescine amidohydrolase (AguB), both of which are involved in conversion from agmatine into putrescine. AguA and AguB were expressed in S. ruminantium. Hence, we concluded that S. ruminantium has both ornithine and agmatine pathways for the synthesis of putrescine.